Panbela Therapeutics Inc PBLA:OTCQB

*Data is delayed | Exchange | USD
Last | 05/03/24 EDT
0.4102quote price arrow up+0.0289 (+7.5793%)
Volume
49,422
52 week range
0.35 - 300.00
Loading...
  • Open0.41
  • Day High0.4789
  • Day Low0.3901
  • Prev Close0.3813
  • 52 Week High300.00
  • 52 Week High Date05/08/23
  • 52 Week Low0.35
  • 52 Week Low Date04/26/24

Key Stats

  • Market Cap1.991M
  • Shares Out4.85M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta0.90
  • YTD % Change-97.76

KEY STATS

  • Open0.41
  • Day High0.4789
  • Day Low0.3901
  • Prev Close0.3813
  • 52 Week High300.00
  • 52 Week High Date05/08/23
  • 52 Week Low0.35
  • 52 Week Low Date04/26/24
  • Market Cap1.991M
  • Shares Out4.85M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta0.90
  • YTD % Change-97.76

RATIOS/PROFITABILITY

  • EPS (TTM)-406.52
  • P/E (TTM)-0.00
  • Fwd P/E (NTM)-0.08
  • EBITDA (TTM)-25.647M
  • ROE (TTM)-798.16%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-110.28%

EVENTS

  • Earnings Date05/15/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Panbela Therapeutics Inc

 

Profile

MORE
Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is involved in enrolling patients in its randomized double-blind placebo-controlled clinical trial for the treatment of pancreatic cancer. The Company's lead assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X). Ivospemin is a polyamine analog designed to induce polyamine metabolic inhibition (PMI). Flynpovi is a combination of CPP-1X...
Michael Cullen M.D.
Chairman of the Board
Jennifer Simpson Ph.D.
President, Chief Executive Officer, Director
Susan Horvath CPA
Chief Financial Officer, Vice President - Finance, Treasurer, Company Secretary
Address
712 Vista Blvd # 305
Waconia, MN
55387
United States